Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead is well-positioned to maintain its leadership in the ... 30.2-month median progression-free survival and median ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest o ...

Gilead Sciences (NASDAQ ... Overview of Peer Analysis The peer analysis summary presents essential metrics for Vertex Pharmaceuticals, Regeneron Pharmaceuticals and Amgen, unveiling their ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Gilead’s HIV sector, populated by dominant HIV treatment Biktarvy and PrEP Descovy, contributed $5.1 billion to the company’s total quarterly sales haul of $7.5 billion, reflecting growth of 7 ...

A Pennsylvania federal district court denied summary judgment to Gilead Sciences, Inc. on the wrongful discharge claim under state law of an employed at-will therapeutic specialist who sold its ...

"Hispanics voted to deport other Hispanics, white women voted to disempower themselves, their daughters and their daughters’ ...